News
10-05-2010, 03:50 AM
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.
More... (http://www.news-medical.net/news/20101005/Merck-Serono-to-present-Erbitux-data-at-ESMO-Congress.aspx)
More... (http://www.news-medical.net/news/20101005/Merck-Serono-to-present-Erbitux-data-at-ESMO-Congress.aspx)